UPDATE – Galectin Therapeutics Reports Financial Results
NORCROSS, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin...
Source: globenewswire.com
International Study Evaluating News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from International Study Evaluating. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In International Study Evaluating Today - Breaking & Trending Today
Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023
NORCROSS, Ga., Oct. 23, 2023 -- Galectin Therapeutics Inc. , the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C....
Source: marketscreener.com
Galectin Therapeutics to Present in Upcoming Conferences
14.10.2022 - NORCROSS, Ga., Oct. 14, 2022 (GLOBE NEWSWIRE) - Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be presenting at two upcoming conferences. On October ...
Source: wallstreet-online.de
Galectin Therapeutics Receives FDA Approval to Proceed with Combination Immunotherapy Trial in Head and Neck Cancer
NORCROSS, Ga., Oct. 12, 2022 -- Galectin Therapeutics, Inc. , the leading developer of therapeutics that target galectin-3, today announced that its Investigational New Drug application for... | October 12, 2022
Source: marketscreener.com
Galectin Therapeutics : Announces $60 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through 2024 - Form 8-K
Galectin Therapeutics Announces $60 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through 2024 ...
Source: marketscreener.com